FDA Approves Olumiant (baricitinib) Treatment for COVID-19 in Certain Hospitalized Adults
May 10, 2022 -- Today, the FDA approved a new indication for Olumiant (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: COVID-19 | Drugs & Pharmacology